Company intelligence / Profile preview
Eilean Therapeutics
Dover, Delaware, United Stateseileanther.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting Phase 1 trials for multiple programs including Balamenib, Eiletoclax, and Lomonitinib. Recently joined the Beat AML Master Clinical Trial to evaluate lomonitinib in FLT3 mutated relapsed refractory AML.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesProteolysis-targeting chimeras (PROTAC)
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
The Leukemia & Lymphoma Society (Beat AML Master Clinical Trial)
Beyond the preview
Go deeper on Eilean Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eilean Therapeutics.